Page last updated: 2024-11-07

2-aminobicyclo(2,2,1)heptane-2-carboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-aminobicyclo(2,2,1)heptane-2-carboxylic acid: amino acid analog; releases insulin; RN given refers to unlabeled cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID115288
CHEMBL ID2074957
CHEBI ID167508
SCHEMBL ID202772
MeSH IDM0049108

Synonyms (42)

Synonym
2-amino-2-norbornanecarboxylic acid
CHEBI:167508
BCH ,
norbornane-2-carboxylic acid, 2-amino-
231A1554-11A8-45CA-9723-19013AAB1BEE
20448-79-7
2-aminobicyclo[2.2.1]heptane-2-carboxylic acid
39669-35-7
AKOS002666381
2-amino-endo-bicyclo(2.2.1)heptane-2-carboxylic acid
2-aminonorbornane-2-carboxylic acid
A814572
bicyclo(2.2.1)heptane-2-carboxylic acid, 2-amino-
b-bch
2-aminobicyclo(2,2,1)heptane-2-carboxylic acid
2-amino-2-carboxy-bicyclo-2,2,1-heptane
CHEMBL2074957 ,
FT-0637999
S6894
gtpl4700
AKOS016044739
SCHEMBL202772
2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid
2-aminobicyclo[2.2.1]heptane-2-carboxylic acid #
J-013331
2-amino-bicyclo[2.2.1]heptane-2-carboxylic acid
2-amino-2-norbornane carboxylic acid
F2100-0080
BS-16529
DTXSID10942624
Q27074943
bicyclo[2.2.1]heptane-2-carboxylic acid, 2-amino-
mfcd00167580
SB74178
CS-0029110
lat1-in-1
HY-108540
F79061
bchbch
bdbm50532382
2-aminobicyclo[2.2.1]heptane-2-carboxylicacid
EN300-29540

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Whereas the reduction in Ca2+i was related to the extracellular glucose concentration in a hyperbolic manner, the increasing component exhibited a sigmoidal dose-response relationship."( Nutrient secretagogues induce bimodal early changes in cytoplasmic calcium of insulin-releasing ob/ob mouse beta-cells.
Gylfe, E, 1988
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monoterpenoidAny terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (33)

Processvia Protein(s)Taxonomy
positive regulation of cytokine production involved in immune responseLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
negative regulation of gene expressionLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
positive regulation of type II interferon productionLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
positive regulation of interleukin-17 productionLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
positive regulation of interleukin-4 productionLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
negative regulation of autophagyLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
response to muscle activityLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
neutral amino acid transportLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
isoleucine transportLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
L-leucine transportLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
methionine transportLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
phenylalanine transportLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
proline transportLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
tryptophan transportLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
tyrosine transportLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
valine transportLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
alanine transportLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
cellular response to glucose starvationLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
xenobiotic transportLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
response to hyperoxiaLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
positive regulation of glial cell proliferationLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
thyroid hormone transportLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
cellular response to lipopolysaccharideLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
amino acid import across plasma membraneLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
liver regenerationLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
transport across blood-brain barrierLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
L-histidine transportLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
cellular response to L-arginineLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
L-leucine import across plasma membraneLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
L-tryptophan transmembrane transportLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell apoptotic processLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
positive regulation of L-leucine import across plasma membraneLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
amino acid transmembrane transportLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
protein bindingLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
amino acid transmembrane transporter activityLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
aromatic amino acid transmembrane transporter activityLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
neutral L-amino acid transmembrane transporter activityLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
L-leucine transmembrane transporter activityLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
L-tryptophan transmembrane transporter activityLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
antiporter activityLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
thyroid hormone transmembrane transporter activityLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
peptide antigen bindingLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
L-amino acid transmembrane transporter activityLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
lysosomal membraneLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
cytosolLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
plasma membraneLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
basal plasma membraneLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
membraneLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
basolateral plasma membraneLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
apical plasma membraneLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
microvillus membraneLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
intracellular membrane-bounded organelleLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
extracellular exosomeLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
external side of apical plasma membraneLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
amino acid transport complexLarge neutral amino acids transporter small subunit 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID681113TP_TRANSPORTER: inhibition of L-tryptophan uptake in Xenopus laevis oocytes2001The Journal of biological chemistry, May-18, Volume: 276, Issue:20
Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters.
AID1626057Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by resazurin dye-based fluorimetric analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
AID1626062Inhibition of LAT1 in human MCF7 cells assessed as potentiation of cisplatin-induced antiproliferative activity by measuring reduction in cell viability at 100 uM measured after 24 hrs by resazurin dye-based fluorimetric analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
AID1626061Inhibition of LAT1 in human MCF7 cells assessed as potentiation of bestatin-induced antiproliferative activity by measuring reduction in cell viability at 100 uM measured after 24 hrs by resazurin dye-based fluorimetric analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
AID1626039Competitive inhibition of [14C]-L-leucine uptake at LAT1 in human MCF7 cells preincubated for 5 mins followed by addition of substrate measured during 5 mins by liquid scintillation counting2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
AID1626068Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability at 100 measured after 72 hrs by resazurin dye-based fluorimetric analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
AID1626063Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability at 100 measured after 48 hrs by resazurin dye-based fluorimetric analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
AID1626065Inhibition of LAT1 in human MCF7 cells assessed as potentiation of bestatin-induced antiproliferative activity by measuring reduction in cell viability at 100 uM measured after 48 hrs by resazurin dye-based fluorimetric analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
AID1626123Drug uptake in human MCF7 cells assessed as LAT1 mediated drug transport per mg of protein at 100 uM after 30 mins by HPLC analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
AID1231902Inhibition of LAT in human LNCAP cells assessed as inhibition of [3H]-L-leucine transport by liquid scintillation counting analysis2015Journal of natural products, Jun-26, Volume: 78, Issue:6
LAT Transport Inhibitors from Pittosporum venulosum Identified by NMR Fingerprint Analysis.
AID1169512Inhibition of eGFP-tagged human B0AT2 expressed in HEK293 cells at 5 mM measured within 10 mins by [3H]proline uptake assay2014Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
Loratadine and analogues: discovery and preliminary structure-activity relationship of inhibitors of the amino acid transporter B(0)AT2.
AID1626070Inhibition of LAT1 in human MCF7 cells assessed as potentiation of bestatin-induced antiproliferative activity by measuring reduction in cell viability at 100 uM measured after 72 hrs by resazurin dye-based fluorimetric analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
AID1626072Inhibition of LAT1 in human MCF7 cells assessed as potentiation of cisplatin-induced antiproliferative activity by measuring reduction in cell viability at 100 uM measured after 72 hrs by resazurin dye-based fluorimetric analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
AID1626059Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability at 100 measured after 24 hrs by resazurin dye-based fluorimetric analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
AID1315283Inhibition of LAT3 in human LNCAP cells assessed as inhibition of [3H]L-leucine uptake at 10 mM after 15 mins by liquid scintillation counting method relative to control2016Journal of natural products, 05-27, Volume: 79, Issue:5
Bioactive Dihydro-β-agarofuran Sesquiterpenoids from the Australian Rainforest Plant Maytenus bilocularis.
AID1626040Potency index, ratio of IC50 for 2-amino-2-norbornanecarboxylic acid to IC50 for test compound for inhibition of [14C]-L-leucine uptake at LAT1 in human MCF7 cells2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
AID1626066Inhibition of LAT1 in human MCF7 cells assessed as potentiation of cisplatin-induced antiproliferative activity by measuring reduction in cell viability at 100 uM measured after 48 hrs by resazurin dye-based fluorimetric analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (162)

TimeframeStudies, This Drug (%)All Drugs %
pre-199044 (27.16)18.7374
1990's32 (19.75)18.2507
2000's49 (30.25)29.6817
2010's33 (20.37)24.3611
2020's4 (2.47)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 14.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index14.53 (24.57)
Research Supply Index5.12 (2.92)
Research Growth Index4.47 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (14.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.60%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other165 (99.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]